Newagebebs. You sure overwhelmed us with facts on why Iplex is dead, so I guess that's why you deleted your post. Your suppositions on why it's dead reminds me of another poster here.
So Newagebios, are you saying it is completely dead, and will never be resurrected? And it's value as a patented drug is zero? And it's intellectual property rights are worthless? And is that based upon your medical/science/pharma background, or your biotech analysis background?
I think Terry had dinner with one of his IDs. My kids used to have tea parties with imaginary friends, so maybe Terry did too. Could have been Bert & Ernie.
He has that leeway, and he may want to use it in a hurry, as AbbVie's change of heart has torpedoed Shire's market value, sending shares down more than 25%. Such weakness could galvanize another suitor to step in and start the process all over again, something Shire, already wounded from one canceled merger, would probably prefer to avoid.
So, Shire's ($SHPG) $55 billion union with AbbVie ($ABBV) probably isn't happening, as changing regulations have gutted the incentives that brought the bottom-line-minded suitor to the table in the first place. But, on the bright side, the U.K. drugmaker is in line for a $1.6 billion breakup fee, cash that could fund a major M&A push, and with renowned dealmakers in its executive ranks, Shire may not be lonely for long.
Now that AbbVie is effectively out of the picture, Shire can get back to the serial acquisitions for which it has been known under CEO Flemming Ornskov, who has presided over 6 buyouts in less than two years on the job. And, if unnamed-source news stories are to be believed, the company isn't wasting any time: Reports have linked Shire to multibillion-dollar offers for NPS Pharma ($NPSP), whose rare disease focus would augment the company's existing expertise, and Cubist Pharmaceuticals ($CBST), a global leader in antibiotic R&D.
In the past, analysts have speculated that Shire may have an eye one of Sarepta Therapeutics ($SRPT) and Prosensa ($RNA), makers of promising treatments for Duchenne muscular dystrophy, or perhaps ThromboGenics, developer of the eye drug Jetrea, a company that announced earlier this year that it was looking into strategic alternatives.
In the run up to AbbVie's final offer, Shire was reportedly scouting for deals that could increase its market value and make itself effectively unacquirable, a process that was severely hamstrung by the U.K.'s opaque and far-reaching takeover code. Under the rules, AbbVie's interest made it so that Shire could not strike any deal worth 10% or more of its market cap, which was about $45 billion at the time.
Now, free of such constraints, Shire and its wallet--soon to be $1.6 billion heavier--can get back in the M&A market. And Ornskov is likely well-prepared, telling The Wall Street Journal in June that, "given leeway, there are a few phone numbers I can execute on immediately."
Thanks for repeating yourself Terry. What's your point? Repeat, Repeat, Repeat. Better yet, where are your facts to back up your claims? Again!!
Short should hope there is no class action lawsuit, as his legal bills might end up to be higher than what he has earned the last few years. He should fear the wrath of shareholders burned a 2nd time by a rice bran snake oil salesman. Hopefully, for his sake, he does the right things going forward.
I tried to research what other biotechs announced an effective combination therapy in June from a clinical/medical trial results. The only thing in June that Insmed announced was a breakthrough therapy designation. They announced the culture conversion info in April. I don't know if a liposomal formulation would be considered a combination therapy.
Insights from a Research Firm: A Golden Age for R&D Should Yield More Breakthrough Drugs
A new wave of innovation looks to be underway. “A number of drugs with enormous potential are in development,” says portfolio manager Jonathan Knowles. “Medical science appears to be on the brink of a paradigm shift in the treatment of many troubling conditions. One area that’s particularly exciting is immunotherapy — medicines that harness the power of the immune system to combat cancers and other diseases.”
Some drugs in development offer the promise of treatments that are much
more effective than existing therapies —
and it’s not just small biotech firms that are innovating in this way.
For example, one of Europe’s larger pharmaceutical firms recently reported some remarkable clinical trial data for a new heart drug. Compared to one of the most widely prescribed generic drugs on the market today, the new drug reportedly reduced cardiovascular deaths by 20%. “Some recent trial data have exceeded expectations, bolstering hopes for a real breakthrough medicine for the treatment of heart failure,” says investment analyst Laura Balan.
Other medicines have the potential to open up new markets by addressing hitherto unmet medical needs — much as hepatitis C cure* Sovaldi has since its launch in December 2013. Gilead Sciences’ novel drug generated
$5.75 billion in sales in its first six months and looks set to become a record-breaking revenue generator. Gilead had earnings (before interest, taxes, depreciation and amortization) of about $5 billion in 2013.
Cystic fibrosis — a life-shortening condition in which malfunctioning mucus glands progressively overwhelm respiratory and digestive systems — is another disease that was once regarded as untreatable. That’s not necessarily true anymore. In June 2014, for example, a U.S.-based biotech firm announced medical trial results that suggest an effective combination therapy for this devastating genetic disease may be on the horizon.
Terry. Believe it or not our sentiment with you is also amusing. We are amused that you can't post facts, you do not write coherent sentences, and that you are a legend in your own mind. You might be taken seriously as a message board poster if you could report facts, not suppositions, and stop posting lies, distortortions, and fabrications. But, I won't bet on it.
If you listen to the chat at about the 5 minute mark, you hear part of the discussion where Poland and UK were the members reviewing Insmed's application, and they were excited about the progress they saw from the trials. They encouraged Insmed to submit the application for all CF and NTM patients, and not restrict the labeling. Lewis said this was about the best they could expect in their hopes to have an approval after they submitted their application.
I wonder if that restriction free labeling would allow Insmed to go after indications of TB and other lung maladies?
RIBT is valued at about 1 x sales. It's market cap and revenue are about 35-36 million dollars. There is absolutely no reason why a company this size is even a public company, especially in the food business. In the long run, if what you are stating about his friends buying part of the company is true, why don't they buy the whole enchilada. Then it could become job security for Short. How much time does he need to prove to everyone that he is a magnificent CEO, and will make everyone money. If you owned the whole business, and he was spending all of your money, how much time would you actually give him to be successful? I know private companies that have much more sales than this in a variety of businesses, and actually make a profit. A good businessman would give Short some ultimatums and goals, and hope that he makes a profit. Otherwise he would be gone. The Board of Directors is not capable of giving that direction to Short, since he had a hand in getting them to be on the Board. This is not an uncalled for attack on Short. It's an honest assessment of his ability to run a profitable company.
He's just another executive that can't speak the truth, based upon historical performances. Rice Bran is different that sun glasses and boxer shorts.
In June 2014, It was accepted by the SEC not to allow access to whatever agreement was made under FIA til 2021